Introduction Dopamine D2 (DA2) agonists are a first line treatment option in young Parkinson's patients with mild to moderate symptoms. DA2 agonists are known to cause depression of cardiac functions with decrease in heart rate. A recent European multicentre study [1] found a relationship between the use of DA2 agonists in Parkinson's disease (PD) and heart failure (HF) especially in early phase of therapy.
Systolic blood pressure (SBP) and brachial pulse rate (PR) for group 1 (18-40 years) and group 2 (40-55 years) in supine and standing position during screening (BL), UPT and SS phase Introduction Metabotropic Glutamate Receptor 5 (mGluR5) negative allosteric modulators (NAM) are suggested as a treatment of some psychiatric disorders such as anxiety. The PK profile and PD effects of many mGluR5-NAMs have been studied and reported. However, PK-PD relationship and the potential impact of circadian rhythm (CR) on this relationship in clinical settings needs further elucidation.
Subjects and methods
This report is a retrospective analysis of data obtained from 18 young healthy female subjects aged 18-37 y who participated in a phase I clinical trial that evaluated some pharmacokinetic characteristics of a mGluR5-NAM medicinal product. Medical history and complete medical examination indicated the mental and physical healthy states of all participants. The test drug (TD) was a CYP3A4 and 1A1 substrate with Log P between 4.5 and 5, t max of 2 hours, t 1/2 of 8 h and plasma protein binding >97%. The TD was given in an escalating bi-daily dose level design over a period of 3 days, followed by a 9 days steady state (SS) period. we studied the following data: difference between plasma levels obtained 2 h after morning and evening TD administration on all dosing days; morning and evening rate of TD absorption (i.e. difference between levels obtained just before dosing (0 h) and levels obtained 2 h post dose) on Day7 of SS, and difference between levels obtained at 2 h and 4 h post evening dosage on Day 7 of the SS period.
Results Mean plasma levels obtained post morning dose were higher than those obtained after evening dose (P < 0.0001).
Morning absorption rate was higher than evening rate (P < 0.0001). Levels obtained at 4 h post evening dosage were higher than those obtained at 2 h post evening dosage in 78% of subjects (P < 0.04). Observed mental adverse reactions (MARs) were insomnia accompanied by significant behavioural disorders, e.g. anxiety in 72%, visual hallucination, mainly nocturnal, in 61%, and symptoms of cognitive dysfunction, severe enough to interfere with daily functioning in 67% of subjects.
Discussion
The intra-subject differences between morning and evening levels can be explained by the impact of CR on factors controlling drug absorption such as low nocturnal expression of lipophilic drug transporters leading to delay in reaching peak levels, giving a false conclusion of a low c-max value when assessed at a time point matching morning one, i.e. 2 h post dose. Lack of PK/PD relationship with predominance of nocturnal MARs could also be explained by CR-related decrease in evening hepatic and brain phase 1 enzyme activity, hepatic blood flow (BF) and serum albumin level together with increase in nocturnal cerebral BF causing increase in nocturnal serum TD unbound fraction (fu), higher CNS TD levels and appearance of nocturnal serious MARs.
Conclusion
We suggest (1) assessment of post-dose concentrations of CNS drugs should include fu, (2) phase I clinical trials designed to evaluate PK properties of psychiatric drugs should be conducted not only in the morning but also in the evening. This would reveal existing difference between daytime and nocturnal PK profiles, help dose optimization and minimize MARs which is of paramount importance especially in the vulnerable psychiatric patients. A clinical trial is planned to confirm our observations.
Introduction In order to improve the inclusion of older patients in pre-authorisation trials, the ICH E7 guideline was adopted by regulatory bodies and pharmaceutical industry in 1994. The guideline requires a minimal number of older subjects for trials concerning diseases characteristically associated with ageing (majority of database ≥65 ys) and for diseases present in older patients (>100 subjects ≥65 ys). The present study evaluated the number of older subjects in trials of recently authorised medicines indicated for diseases frequently present in older patients.
Methods Twelve medicines were included (Table 1) , indicated for diseases frequently present in older patients. The number of older subjects included in the phase 2 and 3 trials was extracted from the European public assessment reports, WHO trial registry and published clinical trials. Results 116 trials were included. Information about subjects ≥65 and ≥75 ys was provided in 39% and 48%, respectively. In trials for indications characteristically associated with ageing (n = 7), five included >50% subjects aged ≥65 ys. Trials investigating medicines for indications present in older people (n = 5), the median number of subjects ≥65 ys was 108. See also Table 1 .
Conclusions
This study shows that the number of older subjects in clinical trials varies greatly. Especially in trials for indications not characteristically associated with ageing, but present in older people, a limited number of older subjects was included.
Introduction Medication non-adherence accounts for substantial worsening of disease outcome, death and increased healthcare costs. Insight into risk factors is important to reveal non-adherence and optimise therapy. We investigate nonadherence and the impact of depression and anxiety disorder on medication non-adherence in a large cohort study sample in a naturalistic settings. The effects of other patient-, disease-and treatment related risk factors were also studied.
Methods
We have selected all participants who used medication (n = 1899) at the four year follow-up of the NESDA cohort of 2402 participants (age 22-69 yr). The primary outcome variable was medication non-adherence measured with the Medication Adherence Rating Scale (MARS). A distinction was made between intentional and unintentional adherence.
Potential predictor variables included patient-, disease-, and treatment-related factors, and were tested in univariate and multivariate analyses.
Results
In multivariate analyses, current depression was the strongest independent predictor of non-adherence compared to no lifetime depression or anxiety diagnosis [OR = 1.71; P = .01]. Remitted depression or anxiety diagnosis [OR = 1.55; P = .003] and current anxiety disorder [OR = 1.46;P = .047] were also independently associated with medication non-adherence. A combined diagnosis of depression and anxiety [OR = 1.41; P = .09] displayed a similar trend with borderline significance. Being male [OR = 1.32; P = 0.01] and being younger [OR = 0.91; P = 0.03] were associated with medication non-adherence. Explorative analysis of medications revealed an association of fixed dose regimens medication adherence and variable dosing with non-adherence. Intentional, but not unintentional non-adherence was associated with type of medication. Unintentional non-adherence was associated with less years of education.
Conclusion Apart from acknowledging current depression, remitted depression or anxiety and a current anxiety diagnosis appeared independent risk factors for medication nonadherence. Since depression and anxiety are highly comorbid with other medical conditions, physicians should address medication non-adherence, even when depression or anxiety patients are in symptomatic remission.
STABILITY ANALYSIS OF CLUSTERING OF NORRIS' VISUAL ANALOG SCALE Z Guan, X Chen, JMA Van Gerven, JL Hay & MD Kam Centre for Human Drug Research, Leiden, the Netherlands
The 16 visual analog scales (VAS) measuring subjective feelings of alertness and mood as described by Norris [1] and Bond and Lader [2] are frequently used in clinical research. Clear and efficient analysis of these VASs is a challenge in practice, either analyzing these items separately or simultaneously. Reducing the dimensions of the scores is crucial. A three-way clustering of 16 items proposed by Bond and Lader [2] is widely cited by researches. However, there are concerns about the stability of this clustering especially with regard to sample randomness, drug-type randomness and the way of calculating the representative score for each cluster. It is also unclear to which extent the effects on individual VAS differ among distinct drug classes. The aim of this study was to investigate an optimized clustering of Norris' 16 individual VASs for different prototype drugs.
1560, 944 and 1687 VAS observations from 142, 86 and 69 healthy male subjects treated with a cannabinoid receptor agonist (delta-9-tetrahydrocannabinol), a muscarinic antagonist (scopolamine), two benzodiazepines (midazolam and lorazepam) and placebo, which were collected at CHDR between 2005 and 2012, were pooled for this study.
Consensus clustering [3] was performed to test the stability of clustering over samples and over drug type. Exploratory factor analysis (EFA) [4] was used as a clustering algorithm. Bootstrapping was chosen as the resampling scheme. Stability analysis was performed on three clusters, and then on other alternative way of clustering. Heatmap visualization (HV) and empirical cumulative distribution (ECDF) were created to evaluate the result of stability analysis. Finally, two new ways of combining item scores for each cluster (average method and penalty method) were presented.
HV and ECDF showed instability for three-way clustering and suggested instability over the three drug classes. Based on the likelihood ratio test within the EFA framework, twoand four-way clustering were also tested. HV and ECDF suggested that the two-cluster assumption was superior. After excluding two unstable items ('Interested-Bored' and 'Withdrawn-Gregarious'), a clear result supported two clusters, which included cluster named 'sedation and impairment' (item 1, 3, 4, 5, 6, 9, 11 and 12 of Bond's original paper) and cluster named 'mood' (item 2, 7, 8, 10, 13 and 14 of Bond's original paper).
In summary, a two-way clustering proved to be sufficiently stable, even between different drugs, based on the consensus clustering method with EFA and bootstrapping. Calculating the cluster score by averaging the summed item scores method is recommended to be used for calculating the cluster combined scores.
Introduction Several studies demonstrated the effect of medication review on the reduction of drug related problems (DRPs) and hospital (re-)admissions. However, these studies had a monocenter design, focussed on elderly patients and were not conducted in an outpatient setting [1] [2] [3] .
Therefore, this multicenter randomised clinical trial (RCT) aims to examine the effect of medication review on drug related problems (DRPs) in outpatient cardiology patients compared to usual care.
Methods In this RCT, intervention patients received a multidisciplinary (physician, patient, pharmacist) medication review before their consult to the cardiologist. The control group received usual care. Adult outpatient cardiology patients without medication management assistance were included. Patients were excluded when their electronic medication records were inaccessible or a medication review in the past six months was done. There were no restrictions on age and the number of drugs used.
Results 175 patients (mean age 66.0 (SD ± 12.4) years, 58.8% male) were included in this RCT. Intervention (n = 90) and control group (n = 85) were comparable at baseline with respect to age, gender, number of (cardiovascular) drugs and number of co-morbidities. The mean number of drugs used by each patient was 7.9 (SD ± 3.9) of which 61% was cardiovascular related. At baseline, the mean number of DRPs did not differ between intervention and control group (1.1 (SD ± 0.1) versus 0.9 (SD ± 0.1)). In 54 % of the DRPs cardiovascular related drugs were involved. The most frequent DRPs could be categorized as 'incorrect use' (16%), followed by undertreatment (15%) and insufficient drug monitoring (15%). After 1 month the mean number of DRPs was 0.3 (SD ± 0.1) in the intervention group versus 0.8 (SD ± 0.1) in the control group (decrease: 0.8 vs 0.1 (P < 0,001: two sample t-test)). DRPs in the categories undertreatment, inappropriate drug formulation and incorrect use were most often solved.
Conclusion This randomised clinical trial shows that medication review in patients with a scheduled visit to the outpatient cardiology ward significantly decreases the number of DRPs. Performing a medication review predominantly decreased drug related problems in the categories of undertreatment, inappropriate drug formulation and incorrect use.
Introduction Collaboration of pharmacists and physicians for medication reviews has increased interest over the years [1] . Less is known on differences of both professions and students' knowledge [2] . The aim is to study if pharmacy and medical students differ on pharmacology and pharmacotherapy (P&P) knowledge and skills.
Methods A cross-sectional design was used to test P&P knowledge in pharmacy and medical master students. A 50 question standardized formative assessment on bachelors' level knowledge and skills was developed, containing the 3 domains: basic knowledge, case-based knowledge and skills and 8 subdomains: 1) pharmacodynamics, 2) pharmacokinetics, 3) interactions and side-effects, 4) medication groups, 5) prescribing, 6) prescribing in special groups, 7) drug information, regulations and laws, 8) recipe writing. The assessment was validated on concurrent validity by an expert panel. Internal consistency, with Guttman Labda, ranged from 0.5-0.7, which is acceptable for formative goals [3, 4] . Mean scores in % per group on the (sub)domains of the assessment were compared with an unpaired t-test and an ancova with covariates: age, sex, previous studies, study duration and inclusion year.
Results A total of 602 students were included (451 medical, 151 pharmacy students; period August 2010-July 2012).
Response rates were 80.8% overall. On basic knowledge pharmacy students outscored the medical students with large effect sizes (77.0% vs 68.2%, P 0.000, δ 0.88), on skills the medical students outscored the pharmacy students with a medium effect size (68.6% vs 50.7%, P 0.000, δ 0.57). For case-based knowledge differences were in favor of the pharmacy students with a very small effect size (73.8% vs 72.2%, P 0.007, δ 0.15). Pharmacy students significantly outscored the medical students on five of the eight subdomains with small to large effect sizes. Medical students outscored the pharmacy students on writing a recipe the with large effect sizes (68.6% vs 50.7%, P 0.000, δ 0.57).
Conclusion Pharmacy master students outscored medical master students on basic knowledge on pharmacology. On case based knowledge differences were significant, but too small to be relevant. On skills medical students outscored pharmacy students. It is likely that both students' knowledge can complement each other. Therefore, collaborations on the level of education can be useful.
Introduction Colorectal Cancer (CRC) is a common disease in the western world. Anti-EGFR therapy (i.e. cetuximab) is the first choice treatment for patients with metastatic CRC. However, not all patients benefit from this treatment, which is caused by a constitutive active K-ras protein. About 40% of CRC cells have such a mutated K-ras gene that results in EGFR independent signaling. For that reason, these patients are excluded from treatment with anti-EGFR drugs.
Since there is hardly any other options available to treat K-ras mutated CRC cells, we are investigating whether the auto-active form of K-ras can be de-activated, rendering these cells again susceptible for anti-EGFR therapy.
Previous experiments showed that treatment of K-ras mutated cells (LoVo) do benefit from anti-EGFR therapy when cells are co-incubated with simvastatin. Simvastatin is an HMG-CoA reductase inhibitor, resulting in reduced production of farnesyl pyrophosphate and geranylgeranyl pyrophosphate. These products are lipophilic and anchor K-ras to the inner-membrane which activates downstream signaling. Our hypothesis was that by preventing prenylation of K-ras, K-ras will not attach to the inner-membrane, and explains our finding that the proliferation pathway had become EGFR dependent.
Methods LoVo (K-ras mt) and SW48 (K-ras wt) cells were seeded in Nunc TM glass 8-chamber slides at density of 20 000 cells/well and cultured for 24 h. After 24 h, medium was refreshed with medium with or without simvastatin (2 μM) and cultured for another 24 h. Cells were fixated with 2% PFA, permeabilized using 0.1% Saponin+2%PFA, incubated with K-ras mouse anti-human antibody (1:200) and incubated with Alexa 488 goat anti-mouse antibody (1:200). Vectashield-Dapi was added to stain the nucleus.
Results
Observation with confocal microscopy revealed that K-ras is present in both wild type and mutant CRC cells. K-ras is located at the inner-membrane of untreated LoVo cells and spread throughout the whole cell in SW48 cells. LoVo cells treated with simvastatin showed translocation of K-ras from the inner membrane to the cytoplasm. In the wild type cell line (SW48), simvastatin had no effect on the location of K-ras.
Conclusions From these results we concluded that mutated Introduction RAS and RAF mutations result in consecutive activation of the mitogen activated protein kinase (MAPK) pathway, involved in a.o. cell proliferation and survival. Inhibition of MAPK kinase (MEK) can block multiple downstream pathways. RO4987655 is an oral MEK inhibitor (Figure 1) . A phase I/II study was performed to assess the maximum tolerated dose (MTD), safety, PK/PD profile and anti-tumor effect of RO4987655. Ocular toxicities are a known class effect of (MEK) inhibitors.
Methods
The phase I part of the study consisted of dose escalation of RO4987655 at doses of 1.0 to 2.5 mg once daily(QD) and 3.0 to 21 mg total daily dose administered twice daily (BID), every day of a 28 day schedule. The phase II expansion part was performed with the recommended phase II dose (RP2D) of 8.5 mg BID in 4 parallel groups of patients with specific tumor indication and specific mutation on the MAPK pathway. Ophthalmologic examinations including fundoscopy and optical coherence tomography (OCT) were performed at baseline/screening and throughout treatment.
Results A total of 145 patients were enrolled: in Part I, 49 patients, in Part II (expansion phase), 96 patients were enrolled, and 95 patients were treated. The most common AEs were diarrhea, rash, retinal detachment, peripheral edemas, vomiting, increased blood CPK, and nausea. The incidence of AEs was similar across all four cancer groups in part II. In part I, 27% of patients experienced eye related toxicities, which included blurred vision, serous retinal detachment (SRD), photopsia, corneal erosion, dry eyes, periorbital edema, chorioretinopathy, punctuate keratitis and 1 case of retinal vein occlusion (RVO). In part II, ocular toxicities were observed in 67% of patients and included visual impairment, SRD ( Figure 2 ) blurred vision, angle closure glaucoma, and eyelid edema. No RVO was observed. Sudden onset of impaired vision (after 1 day) was observed. Majority of ocular toxicities was of mild/moderate intensity and resolved without dose modification or interruption and never led to withdrawal of study drug.
Conclusion Ocular toxicities were frequently reported AEs with RO4987655 but always reversible, temporary and well manageable. 
Figure 1
Chemical structure of RO4987655
Figure 2
Introduction Polymedicated patients, including nursing home residents, have an increased risk of experiencing adverse drug reactions, problems with drug choice, dose and treatment duration, and probably undertreatment. In addition, the management of such patients is often challenging due to complex impairment and/or comorbidity [1, 2] . The ultimate goal is to develop a clinical decision support system within the SCREEN study (ZonMw) to support clinical practice in nursing homes and homes for the aged. The aim of this study was to evaluate to which extent laboratory data, actual medication, medical history and drug indication are used in daily practice.
Methods Healthcare professionals including nursing home physicians, community pharmacists and general practitioners, were requested to perform medication reviews for 3 different cases (A, B, C) in three different situations in relation to the amount of available information at a time: stage 1 only with the medication list, 2 adding the laboratory data and the reason for admission, and stage 3 adding the medical history. The number of remarks and their clinical relevance was retrospectively assessed, per stage, by our expert panel in order to establish the golden standard.
Results
The results after the comparison with the golden standard medication are listed in Table 1 . Min. score (P) 2 (14%) 4 (21%) 2,7 (10%) Mean score (P) 5,6 (40%)* 6,8 (36%)* 9,6 (36%)* SD 2,6 4,2 5,1 *Statistically significant for case A (P = 0.001).
Medication problems which were identified by few participants included the addition of new medication and switching medication according to clinical data and/or guidelines. On the other hand, benzodiazepines related remarks were well identified together with dose reduction and/or drug stopping due to laboratory values or lack of indication.
Conclusion
The large variation in the quality of these medication reviews, as well as a the low mean quality, highlights that information is not correctly used or wrongly interpreted, irrespective of the available information.
Introduction Capecitabine, an oral pre-prodrug of 5-fluorouracil (5FU), has largely replaced intravenous 5FU in the treatment of colorectal cancer. Few studies, however, have examined its use in anal carcinoma (AC). There is clear rationale for the use of capecitabine with radiotherapy (RT) [1] , such as in preoperative RT for rectal cancer [2] , and we recently demonstrated that in AC 825 mg m −2 b.i.d. on irradiation days is feasible [3] . Here, we studied a cohort of AC patients treated with capecitabine + mitomycin C (MMC) and RT, and compared outcomes with those of patients treated with 5FU + MMC and RT. Conclusions Response rate, LRC, and OS were similar for patients treated with 5-FU or capecitabine. Acute skin toxicity was more prevalent with capecitabine + IMRT, which may be the result of longer duration of combined exposure to chemotherapy and RT, or the omission of a planned RT treatment break. Our study population reflects daily practice and the results indicate that capecitabine combined with MMC and IMRT is an effective treatment for locally advanced AC.
Methods
Introduction Medication surveillance is not routinely performed for intravenous cytostatic drugs. However, cancer patients often use a large number of comedication and therefore the risk of interactions increases [1] . The aim of this study was to determine the prevalence and relevance of interactions with cytostatic drugs in ambulatory cancer patients receiving intravenous cytostatic treatments.
Methods Since October 2010, all ambulatory cancer patients starting with an intravenous cytostatic treatment in the hospital were included. At the start of the cytostatic regimen, the hospital pharmacist performed the medication surveillance and imported the ambulatory medication into the system. At the same time, the cytostatic scheme was sent to the community pharmacy where patients were registered. When new drugs were prescribed, the community pharmacist was responsible for the medication surveillance. Interactions that might occur would have to be reported to the hospital pharmacist.
Results A total of 491 patients was included of which 287 were female (58.5%). In 27 patients (5.5%) an interaction alert was encountered. These interactions are shown in Table 1 . The interactions with valproic acid were monitored during the cytostatic regimen. Once every cycle a blood sample was taken but no differences were found. It was found that not all alerts detected by community pharmacists were reported to the hospital pharmacist.
Conclusion
The results are comparable with a previous retrospective study conducted in the Orbis Medical Centre, where acenocoumarol was also the most frequently involved drug. The responsibility concerning medication surveillance for IV cytostatic drugs needs to be defined and optimized.
Introduction Development of immune-modulating drugs is challenging as assessment of intended pharmacology in healthy volunteers is difficult. Commonly, ex-vivo LPS challenges of whole blood or isolated cells are applied. However, the applicability of the LPS challenge is limited as LPS primarily stimulates germ-line encoded innate-immune TLR4-receptors, and thus does not allow monitoring of pharmacological modulation of the adaptive immune compartment.
Methods
We explored an alternative whole blood challenge, inducing lymphocyte-driven inflammation by the superantigen staphylococcal enterotoxin B (SEB), and compared this to LPS. Further validation was performed by assessing the inhibitory effects of different immune-modulating compounds (MAP kinase inhibitors, calcitriol, methotrexate, protein kinase C, doxycycline, simvastatin), allowing discrimination between effects on monocytes and lymphocytes.
Results SEB induction resulted in the release of a cytokine panel that well-resembled cytokine release observed after physiological lymphocyte stimulation, with clear induction of IL-2, IFN-γ, TNF-α, IL-10 and GM-CSF. Based on TNF-α and IL-2 release, SEB's maximal effect was reached at 100 ng ml −1 . Whereas interindividual variability in EC50 was relatively small for LPS (0.32 ± 0.10 ng ml −1 ), for SEB inter-subject variability was distinctly higher (62 ± 54 ng ml −1 ). MAP kinase inhibitors and calcitriol were effective in inhibiting SEB-induced TNF-α release, a clear inhibiting effect on SEB-induced IL-2 release was observed, implying a direct action of these compounds on the lymphocyte.
Conclusions These data demonstrate that the SEB challenge can be used to estimate the immune-modulating effects of compounds directly acting on the T-lymphocyte population. As such, the whole blood SEB challenge is a useful translational tool in early drug development, especially since immune-inflammation is a target in the development of new treatment modalities for currently poorly-controlled diseases such as rheumatoid arthritis and psoriasis, and even cardiovascular disease.
Introduction
The free pharmacology Teaching Resource Centre (TRC) was created in the 1990s with a unique symbol language to illustrate drug action in the pathophysiological context in a consistent way. First, it was published as hardcopy binder and quickly this traditional pharmacology book was upgraded to an E-learning repository that led to widespread use by students and educators both nationally and internationally. Studying the TRC also has a positive effect on pharmacological learning outcomes as TRC study time correlated with an increase in course grades for the individual student [1] . However, with the introduction of the tablets and smartphones, Leiden students demanded for increased accessibility of pharmacological knowledge, i.e. the TRC. In 2012 novel the TRC apps for iPad and iPhone were developed at Leiden University Medical Centre (LUMC) by a medical student. Objective of the study was to investigate usage frequency, differences in usage and userfriendliness of the apps compared to the website. Moreover, the impact of the apps on the usage frequency of the website was analyzed.
Methods
The hits of TRC website were monitored during a specified period in academic year 2012-2013, i.e. with the apps in place, and compared to the previous year. The number of downloads combined with the geographical location of the download were registered for website and app, respectively. In order to obtain more information about usage at LUMC, a voluntary online survey was conducted among students where a total of 268 medical undergraduates responded.
Results Seven months after the initial release in June 2012, the apps have been downloaded more than 10.000 throughout the world. The TRC website is still frequently used with up to 5000 hits per day before exams. The website is only slightly less used compared to the previous year and 70.4% of the iPad app users (n = 27) indicate to continue to use the website. Further analysis of the survey questions revealed that 37.0% use the app once per week whereas only 13.1% of respondents consult the TRC website similar often. During lectures and seminars the app is used by 33.3% of iPad users while only 7.5% of the respondents use the TRC on a laptop. The overall assessment of the resources is similar which is reflected by 7.4 versus 7.6 points on a 10 point grading scaling for app and website, respectively.
Conclusion
The free pharmacology app is readily available for all health care students and professionals worldwide. The TRC app is easier accessible and used differently with respect to learning situations compared to the website. Only a slight impact on the usage frequency of the website is observed. Due to the success of the apps, further extension of the E-learning program to other platforms is planned. Introduction The ability to deliver the potent anti-cancer agent docetaxel via the oral route enables the development of new treatment regimens. ModraDoc001 is a novel oral formulation containing docetaxel as a solid dispersion. Oral administration of docetaxel is feasible in combination with the CYP3A4 inhibitor ritonavir. Objectives of this study were to determine the safety, maximum tolerated dose (MTD) and pharmacokinetics (PK) of once weekly oral docetaxel (as ModraDoc001) in combination with ritonavir. In the first study docetaxel was given once daily (QD) and in the second study bi-daily (BID).
Reference
Methods Patients with advanced solid tumors, WHO PS ≤ 2, no use of MDR or CYP3A modulating drugs, adequate bone marrow (ANC ≥ 1.5 × 10 9 l −1 , platelets > 100 × 10 9 l −1 ), liver (bilirubin ≤ 1.5 × ULN, ALAT/ASAT ≤ 2.5 × ULN) and renal function (creatinine ≤ 1.5 × ULN or clearance ≥50 ml min −1 ) were eligible. Docetaxel (ModraDoc001 10 mg capsule) and ritonavir (Norvir® 100 mg) were simultaneously given once weekly in a '3 + 3 cohort' dose escalation design. MTD was defined as the highest dose resulting in ≤1/6 probability of causing a dose limiting toxicity in the first 4 weeks of treatment. PK was determined during the first three courses.
Results
In the QD study 48 patients (28 males) were enrolled in 6 dose-levels (30/100, 40/100, 60/100, 80/100, 60/200 and 80/200 mg docetaxel/ritonavir). In the BID study 17 patients (9 males) were enrolled in 3 dose-levels (20/100, 30/100 and 40/100 mg docetaxel/ritonavir BID). Common treatment related adverse events in both studies were fatigue (72%), diarrhea (63%) and nausea (63%), mostly CTC grade 1-2. In the QD study 6 patients experienced a DLT (grade 3 diarrhea (n = 5), grade 3 fatigue (3), elevated ASAT/ALAT (1), grade 4 dehydration (1), grade 3 mucositis (1) and grade 3 vomiting (1)). In the BID study 4 patients experienced a DLT (grade 3 diarrhea (1), grade 3 anorexia (1), grade 3 hemorrhage (1), grade 3 nausea (1), grade 3 mucostits (1) and grade 4 neutropenia (1)). MTDs were 60/200 mg docetaxel/ritonavir QD and 20/100 mg BID. A partial remission was seen in 4 patients (CUP, NSCLC, gastric and breast cancer) and sustained stable disease in 19 patients (10 with NSCLC). Mean Tmax was 2 hours for both docetaxel and ritonavir. Cmax and AUC of docetaxel increased less than proportionally with dose to 162 ng ml −1 (CV = 67%) and 1615 ng ml −1 *hr (81%), respectively after QD and 78 ng ml −1 (79%) and 768 ng ml −1 *hr (57%) respectively after BID administration, at both MTDs.
Conclusions At both MTDs (once weekly 60/200 mg QD and 20/100 mg docetaxel/ritonavir BID, resp.) ModraDoc001 is safe, well tolerated and shows encouraging antitumor activity. The exposure to docetaxel with the daily regimen is comparable to weekly intravenous administration of 35 mg m −2 docetaxel. Phase II studies in solid tumors are planned. Background Information transfer between the hospital and community care setting is frequently incomplete [1, 2] . This study primarily aimed to assess the completeness of medication related information in discharge letters and general practitioner (GP) overviews after discharge.
COMPLETENESS OF MEDICATION RELATED INFORMATION IN DISCHARGE LETTERS AND GENERAL PRACTITIONER OVERVIEWS AFTER HOSPITAL DISCHARGE
Methods An observational study was performed at the Sint Lucas Andreas Hospital. Discharged patients with at least one change in pre-admission prescribed medication were included from the departments of neurology, cardiology, pulmonology and internal medicine. For included patients a Transitional Medication Overview (TMO) containing all pharmacotherapy and allergies was made at discharge. The discharge letters of patients were collected. Two weeks after discharge, medication files were collected from GPs. The TMO information was compared with the information in the discharge letter and on the GP overview regarding correct medication (including correct dose and frequency) and correct allergy documentation. Descriptive data-analysis was used to assess the frequency of correct documented information (primary outcome). Secondary the frequency of correct information on the GP overview was compared between medication information that had and had not been communicated through the discharge letter.
Results
In the study 99 patients were included. The medication related information was complete in 62 (63%) discharge letters and 16 (16%) GP overviews. Incompleteness of discharge letters and GP overviews were mainly caused by non-documentation of medication changes and allergies.
Of the medication information that was documented in the discharge letter, 65% was reproduced on the GP overview, Clinical Pharmacology and Biopharmacy meeting of March 26, 2013 against 47% of the medication information that was not documented in the discharge letter (OR 2.1, 95%-CI: 1.5-2.9).
Conclusion Medication related information is lost in the discharge letter and GP overview. Communication through discharge letters caused a more complete GP overview. Nevertheless, GP overviews did not contain all communicated information.
Information loss can result in discontiniuty of care and unintended represcription of incorrect medication [3] . Future studies should determine the effect of electronic infrastructures on improving information transfer regarding medication related information.
Introduction Roux-en-Y gastric bypass (RYGB) surgery is the most commonly performed procedure in bariatric surgery, greatly reducing stomach size and bypassing much of the small intestine. Hence it may reduce the absorption and bioavai-lability of oral medications, especially modified release products. However, the pharmacokinetics of drugs after RYGB are poorly studied. An in vitro dissolution method simulating the conditions before and after RYGB might be a valuable tool to predict the behaviour of drugs with possible bioavailability problems in vivo. The objective of this study was to develop a gastrointestinal simulation system (GISS) mimicking conditions before and after RYGB for investigating dissolution characteristics of oral medications.
Methods
The GISS is a dissolution method which is based on a design by Schellekens et al. [1] . The GISS enables variation in parameters which are relevant to drug release in vivo: pH, volume, transit time, osmolality and agitation. During the test an oral drug formulation is exposed to solutions simulating stomach, (duodenum) jejunum, ileum and colon in fasting and non-fasting conditions before and after RYGB. Metoprolol immediate (IR) and controlled release (CR) tablets were tested in triplo. Release profiles were determined by measuring the concentrations of metoprolol spectrophotometrically.
Results
The GISS is able to expose an oral dosage form to subsequent environments simulating fasting and non-fasting conditions before and after RYGB. So far, release profiles of the tested products have been studied in conditions before RYGB. In non-fasting conditions after 30 min the release of metoprolol from the IR tablet is complete. From the CR tablet after 300 min almost 30 % of metoprolol is released.
Conclusion A GISS has been developed to study release behaviour of medication during its passage through the gastrointestinal tract in fasting and non-fasting conditions before and after RYGB. Studies in which the situation after RYGB is simulated are in progress. 3 1 Erasmus Medical Center, Rotterdam, the Netherlands, 2 Martini Hospital, Groningen, the Netherlands, 3 University of Groningen and University Medical Center Groningen, Groningen, the Netherlands Background In daily clinical practice adverse drug events are not always recognized by the attending physician. Nevertheless, the physician may be concerned about a possible adverse outcome, although there are no specific indications yet. This phenomenon, described as 'gut feeling' or 'sense of alarm', leads to increased diagnostic procedures to clarify the patient's condition. If this phenomenon applies for ADEs, the number of biochemical tests may be used as a trigger to identify patients at risk of an ADE. Therefore, the objective of this study was to investigate whether the number of biochemical tests increases before the manifestation of ADEs.
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Methods This cohort study was performed in two medical wards in hospital 'TweeSteden' in Tilburg and Waalwijk and three medical wards in University Medical Center in Groningen. All patients admitted to the study wards for more than 24 h using one or more drugs during admission were included. Patient characteristics (age, sex, weight and length), data on diseases (medical history, reasons for admission and diagnoses) and medication orders were collected.
The total number of biochemical tests per day was counted and all tests were assigned to one of eight test groups (among others metabolic tests, therapeutic drug monitoring and haemostasis tests). ADEs included adverse drug reactions and preventable ADEs resulting from a medication error. The causal relation between recorded adverse events and any drug taken by the patient was assessed by at least two pharmacists. Univariate and multivariate cox-regression analyses were performed using the number of biochemical tests carried out in the two prior days as time-dependent variable.
Results
In this study 586 admissions of 557 patients were included. ADEs were identified during 344 admissions (59%). Univariate analysis showed an association between the number of metabolic tests and ADEs (Hazard Ratio (HR) 1.22, 90% Confidence Interval (CI) 1.05-1.41). After correction for possible confounders in the multivariate analysis, this association was not statistically significant (HR adjusted 1.14, 95% CI 0.95-1.36). Neither the total number of tests nor other types of tests were statistically significantly associated with ADEs. However, after univariate analysis a trend towards an increased risk of ADEs was observed for therapeutic drug monitoring (HR 1.16, 95% CI 0.73-1.82) and haemostasis tests showed a trend towards a decreased risk of ADEs (HR 0.88, CI 0.76-1.03).
Conclusions
The number of laboratory tests does not increase prior to an ADE. Therefore, the number of tests cannot be used as a trigger to identify patients at risk of an ADE.
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